Loading...
•
Sep 30, 2022
AbCellera Q3 2022 Earnings Report
Reported strong revenue growth driven by royalties and progress in programs and partnerships.
Key Takeaways
AbCellera reported a significant increase in revenue for Q3 2022, driven primarily by royalties associated with bebtelovimab. The company also saw growth in research fees and advancements in its discovery programs, resulting in a net income compared to a net loss in the same quarter of the previous year. AbCellera maintains a strong cash position to support its strategic initiatives.
Total revenue was $101.4 million, a significant increase from $6 million in Q3 2021.
Net income was $26.6 million, compared to a net loss of $21.4 million in Q3 2021.
Four program starts in the quarter, bringing the cumulative total to 92, up 33% from Q3 2021.
One molecule advanced to Phase 1 clinical trials, bringing the cumulative total to seven molecules in the clinic.
AbCellera
AbCellera
AbCellera Revenue by Segment
Revenue by Segment
Research Fees Revenue
CapyFin.comLicensing Revenue
CapyFin.com Forward Guidance
No specific forward guidance was provided in the earnings report.
Revenue & Expenses
Visualization of income flow from segment revenue to net income